# Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)

> **NCT00298831** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 224 (actual)

## Conditions studied

- Anesthesia, General

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Rocuronium

## Key facts

- **NCT ID:** NCT00298831
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10-27
- **Primary completion:** 2006-05-22
- **Final completion:** 2006-05-22
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2019-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00298831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00298831, "Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00298831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*